Profile cover photo
Profile photo
LDNNow
31 followers -
Naltrexone, autoimmune, cancer, CNS disorders, biotherapy, met enkephalin, OGF, OGFreceptor, TLR4
Naltrexone, autoimmune, cancer, CNS disorders, biotherapy, met enkephalin, OGF, OGFreceptor, TLR4

31 followers
About
LDNNow's posts

Post has attachment
Public
Innovative Alternative Therapies for Chronic Lyme Disease

Kent Holdorf MD shares his findings, views and thoughts in a presentation on Lyme Disease at the AARM Regional Conference, Overcoming Diagnostic and Treatment Challenges of Lyme Disease, Infectious Diseases and CSF, Seattle, Washington, 2017.

In an open-label study by Horowitz of 1000+ patients with Lyme disease and MSIDS, approximately 75% of patients experienced less fatigue, myalgia, and arthralgia when the naltrexone dose was titrated to 4.5 mg at bedtime

Lyme disease/CFS/FM are multisystem diseases with a key component being immune dysfunction. Being able to identify and treat the immune dysfunction (TH1-TH2 shift) that is consistently seen with these illnesses can improve diagnostic accuracy, result in significant symptomatic improvement and significantly increase the likelihood of successful longterm success. Multisystem treatments that address the underlying multisystem abnormalities, including LDN, peptide therapies, T3, cortisol, sargramostim/filgrastim, ozone and low dose heparin can be very effective for non-responsive patients

https://restorativemedicine.org/wp-content/uploads/2017/01/4Holtorf_-Lyme-CFS.pdf


Post has attachment
Public
LDN clinical trial - Immune Effects of Low-dose Naltrexone in ME/CFS

This study that is being conducted by Dr Jarred Younger at University of Alabama is currently recruiting participants (18-65 year olds).
The main objective of this study is to test if naltrexone, when taken in low doses, has an anti-inflammatory effect that may be associated with positive clinical outcomes in people with chronic fatigue syndrome (CFS). In part, the present study, is a continuation of prior work in which we showed that chronic fatigue symptoms are associated with immune activity, and that low-dose naltrexone might exert anti-inflammatory effects in fibromyalgia, which is thought to share some pathophysiological and clinical characteristics with CFS.

https://clinicaltrials.gov/ct2/show/study/NCT02965768#contacts 

Post has attachment
Public
Phase 2 Clinical Trial - Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis (LDN-VA):

“Among the many unproven treatments that are widely used, LDN is of particular interest because results of surveys of patients are particularly impressive, because it is quite safe, and because its benefit is plausible pharmacologically. There is evidence both for modulation of central pain-processing pathways and for down-regulation of inflammatory pathways in microglia.

The proposed study is a randomized, double-blinded, cross-over, placebo-controlled trial in adults with osteoarthritis or inflammatory arthritis and persistent pain. Sixty patients will be enrolled for 16 weeks, during which they will receive LDN for 8 weeks and placebo for 8 weeks. Widely accepted patient-reported outcome measures will be used. The co-primary endpoints are reduction in pain severity or pain's interference with function during 8 weeks of LDN compared to 8 weeks placebo, using the Brief Pain Inventory. Other patient-reported data will be used both as secondary outcomes and as covariates in analyzing determinants of response to treatment.”

https://clinicaltrials.gov/show/NCT03008590 

Post has attachment
Public
Low-Dose Naltrexone Appears Stable for Long-term MS Control:-
Low dose naltrexone (LDN) appears to be safe for patients with multiple sclerosis even when taken long term. In order to investigate, the researchers looked at “behavioral data, clinical laboratory blood values, as well as interpretation of MRIs over a period of 10 years,” they say, and found that patients diagnosed with RRMS who were receiving only LDN experienced no significant adverse effects. Additionally, the authors report LDN “does not appear to increase MRI activity or alter regular blood tests of liver, kidney and hematopoietic function.”
http://www.hcplive.com/medical-news/low-dose-naltrexone-appears-stable-for-long-term-ms-control

Post has attachment
Public
Could Low-Dose Naltrexone be an effective treatment for Hailey-Hailey Disease?

HHD patients treated with LDN report up to 90% healed skin and a reduction in body weight, depression, and suicidal thoughts (if there is a secondary infection, patients report it is important to treat the infection in addition to LDN treatment for HHD). Despite these promising results, there are no published case studies or reports and no clinical studies are testing the use of LDN to treat HHD. These studies are necessary to better understand the mechanism of action and effects of LDN in HHD.

http://www.gratisoa.org/journals/index.php/MML/article/view/79/81

Public
Good to see research on LDN and #Crohns   being studied at Cairo University comparing LDN with sulfasalazine – “Evaluation of Therapeutic Effect of Low Dose Naltrexone in Experimentally-Induced Crohn's Disease in Rats”.

Results:- “The present study showed significant improvement of DAI in rats treated with low dose naltrexone and those treated with combination of naltrexone and sulfasalazine, compared with rats that was treated with sulfasalazine alone.”

Conclusion:- “The current finding could provide new interesting opportunity for developing new therapeutic approaches for treatment of Crohn’s disease. Use of naltrexone, especially in small doses has little side effects making it of interest for treatment of Crohn’s disease. Also, it provides the possibility of reduced doses of other drugs if it used as combined therapy.”

http://www.sciencedirect.com/science/article/pii/S0143417916300348

Post has attachment
A study showing the combination of LDN and l-tetraydropalmatine (l-THP) has shown a promising treatment for the prevention of cocaine relapse has been published in The American Society for Pharmacology and Experimental Therapeutics (22 Feb 2016) http://jpet.aspetjournals.org/content/early/2016/02/22/jpet.115.229542.abstract

Post has attachment
LDN Dosing Information:-

In 1979 the effects of taking Naltrexone in low doses (LDN) was discovered. Two years of experimentation to clarify its mechanism were required to study the effects of LDN and were published in 1983 (6). LDN has been prescribed in doses <5mg in the clinical setting since the late 1980s (7). 

There are a lot of questions surrounding what dose people should take with more and more people wanting to use this non toxic biotherapy approach to medicine for various illnesses. Here we will talk about how LDN modifies a biological system through the rebound effect. 

To read the full article with cited references please click here https://1drv.ms/1KL8tSB 

How LDN Works:-
“LDN is a drug that implements the biotherapy approach to 21st century medicine which is all about artificially stimulating the body’s own defences and systems in order to restore control over chronic and systemic diseases. LDN has a demonstrable safety record with no toxicity issues, is orally delivered, making it an attractive therapy for many diseases” - LDNNow. 

To read more please click here 
http://1drv.ms/1PpM5Pc 

Post has attachment
The Medicine Store in New Hampshire - Low Dose Naltrexone. Marty has been dispensing LDN for over 8 years and is more than just a compounding pharmacist. In 1995 Marty began the process of obtaining additional training in the area of natural medicine.  He has received a Diploma of Clinical Nutrition (DCN) and a Diploma in Herbology (Dip. Herb.).  To rea more ......
https://www.facebook.com/notes/ldnnow/the-medicine-store-in-new-hampshire-low-dose-naltrexone/10153451815063391
Wait while more posts are being loaded